Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B. longum 2012 is a genetically engineered strain of the probiotic bacterium Bifidobacterium longum, developed as a component of an oral protein vaccine platform. It is specifically modified to display the galacto-N-biose/lacto-N-biose I-binding protein (GLBP) on its cell surface, which serves as an anchoring mechanism for tumor-associated antigens. In preclinical research for Wilms' tumor 1 (WT1) immunotherapy, B. longum 2012 is used as a control or intermediate strain to evaluate the efficacy of antigen-expressing versions like B. longum 420. The platform utilizes the bacteria's natural tropism for tumor environments and its ability to stimulate intestinal immunity via Peyer's patches to induce systemic immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on B. longum 2012.